Arteriosclerosis Obliterans

Common occlusive arterial disease which is caused by ATHEROSCLEROSIS. It is characterized by lesions in the innermost layer (ARTERIAL INTIMA) of arteries including the AORTA and its branches to the extremities. Risk factors include smoking, HYPERLIPIDEMIA, and HYPERTENSION.

Also Known As:

Networked: 477 relevant articles (33 outcomes, 52 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Thromboangiitis Obliterans (Buerger's Disease)
2.	Ulcer
3.	Intermittent Claudication
4.	Myocardial Infarction
5.	Arterial Occlusive Diseases (Arterial Occlusive Disease)

Experts

1.	Wang, Mian: 6 articles (01/2021 - 09/2011)
2.	Li, Wen: 5 articles (12/2020 - 09/2011)
3.	Hoshino, Junichi: 5 articles (01/2018 - 08/2007)
4.	Miyata, Tetsuro: 4 articles (01/2016 - 01/2009)
5.	Kawakami, Masanobu: 4 articles (03/2007 - 04/2002)
6.	Chang, Guangqi: 3 articles (01/2021 - 09/2015)
7.	Wang, Shenming: 3 articles (12/2020 - 09/2015)
8.	Matoba, Satoaki: 3 articles (03/2020 - 01/2018)
9.	Yanishi, Kenji: 3 articles (03/2020 - 01/2018)
10.	Horie, Takashi: 3 articles (01/2018 - 02/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Arteriosclerosis Obliterans:

1.	Epoprostenol (Prostacyclin)FDA LinkGeneric 05/26/1979 - "Successful therapy of advanced arteriosclerosis obliterans with prostacyclin." 06/01/2006 - "This finding suggests that prostacyclin or prostacyclin analogues may act on their receptors on endothelial cells in patients with arteriosclerosis obliterans." 06/01/2006 - "Prostacyclin analogues have been clinically proven to improve ischemic symptoms and prevent the occurrence of vascular events in the lower extremities of patients with arteriosclerosis obliterans. " 06/01/1982 - "Effect of prostacyclin (PGI2) on platelets and fibrinolytic activity in patients with arteriosclerosis obliterans." 04/30/1982 - "Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans."
2.	beraprostIBA 08/01/1997 - "In clinical studies, beraprost sodium exerted a marked effect to improve arteriosclerosis obliterans. " 05/01/2013 - "Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients." 01/01/2002 - "Beraprost, an orally administered PGI2 analogue, is generally well tolerated and appears to be an effective agent in the treatment of patients with Buerger's disease and arteriosclerosis obliterans. " 01/01/2015 - "Beraprost Sodium Protects Against Diabetic Nephropathy in Patients with Arteriosclerosis Obliterans: A Prospective, Randomized, Open-label Study." 01/01/2002 - "Additional well-designed and, where possible, large trials with active comparators are necessary to define more precisely the place of beraprost in the treatment of patients with PAH, Buerger's disease and arteriosclerosis obliterans."
3.	oxidized low density lipoproteinIBA 07/01/1995 - "Removal of LDL from plasma by adsorption reduces adhesion molecules on mononuclear cells in patients with arteriosclerosis obliterans." 01/01/1993 - "We reported here a case of arteriosclerosis obliterans (ASO) in which clinical symptoms and signs were improved after repeated LDL apheresis. " 01/01/1993 - "[Arteriosclerosis obliterans that was improved by LDL apheresis]." 11/01/2012 - "Increment of cerebral blood flow by LDL-apheresis in dialysis patients with arteriosclerosis obliterans: a pilot study." 08/01/1997 - "LDL apheresis has also been approved for the treatment of glomerulosclerosis and arteriosclerosis obliterans."
4.	LDL Lipoproteins (beta Lipoproteins)IBA 01/01/2007 - "Efficacy of low-density lipoprotein apheresis in arteriosclerosis obliterans of the lower extremities: two cases with marked alleviation of clinical symptoms." 06/01/2004 - "Low-density lipoprotein apheresis in a patient with arteriosclerosis obliterans and light chain deposition disease." 01/01/2003 - "Adsorption of low-density lipoprotein (LDL) has been applied in the treatment of arteriosclerosis obliterans (ASO). " 11/01/2003 - "We studied whether low-density lipoprotein (LDL) apheresis alters plasma ET-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans (ASO). " 11/01/2003 - "Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans."
5.	Alprostadil (Muse)FDA LinkGeneric 09/01/2004 - "The purpose of this study was to determine the effect of treatment with prostaglandin E1, Liple, on both the physical and emotional health-related quality of life (QOL) of patients with arteriosclerosis obliterans (ASO). " 05/01/1993 - "[A trial of the use of Vasaprostan in patients with arteriosclerosis obliterans of the lower extremities]." 10/01/1998 - "19 patients with arteriosclerosis obliterans were given PGE1 (20 microg) iontophoretically on the dorsum of the foot. " 07/01/1997 - "Effects of prostaglandin E1 infusion on limb hemodynamics and vasodilatory response in patients with arteriosclerosis obliterans." 01/01/1983 - "Clinical experience with prostaglandin E1 in the treatment of arteriosclerosis obliterans. "
6.	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/01/2007 - "Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans." 12/01/2007 - "Previous studies have suggested that the lower limb arteriosclerosis obliterans (LASO) could be improved by autologous transplantation of either bone marrow mononuclear cells (BM-MNC) or G-CSF-mobilized peripheral blood mononuclear cells (M-PBMNC). " 02/01/2011 - "In this study, we report the comparative result of long-term clinical prognoses for patients with no-option critical limb ischemia (CLI) caused by arteriosclerosis obliterans, who are implanted with autologous bone marrow mononuclear cells (BMMNC; n=74) or G-CSF-mobilized (M)-PBMNC (n=111), as no information is available on how the two treatments compare in terms of long-term prognosis, such as survival or amputation. " 01/01/2018 - "The clinical usefulness of peripheral blood (PB) mononuclear cell (MNC) transplantation in patients with peripheral arterial disease (PAD), especially in those with mild-to-moderate severity, has not been fully clarified.Methods and Results:A randomized clinical trial was conducted to evaluate the efficacy and safety of granulocyte colony-stimulating factor (G-CSF)-mobilized PBMNC transplantation in patients with PAD (Fontaine stage II-IV and Rutherford category 1-5) caused by arteriosclerosis obliterans or Buerger's disease. " 02/01/2006 - "Autolougous transplantation of granulocyte colony-stimulating factor (G-CSF)-mobilized human peripheral blood mononuclear cells (PBMNCs) improves limb ischemia in patients with arteriosclerosis obliterans of lower extremities and with diabetic foot. "
7.	Ticlopidine (Ticlid)FDA LinkGeneric 10/15/1985 - "Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs." 08/01/1987 - "Therapeutic trials in patients with chronic arterial occlusion due to thrombangitis obliterans or arteriosclerosis obliterans, post-myocardial infarction, cerebrovascular thromboembolic disease, subarachnoid haemorrhage, vascular shunts or fistulas for haemodialysis, and sickle cell disease have shown promise for the use of ticlopidine. " 01/01/2002 - "Data from a large, randomised, double-blind, multicentre study indicated that beraprost was as efficacious as ticlopidine in the treatment of patients with peripheral arterial disease (Buerger's disease and arteriosclerosis obliterans). "
8.	Troleandomycin (TAO)FDA Link 12/01/2013 - "Blood samples and clinical characteristics were collected from 38 patients with Rutherford grade I TAO, 30 patients with Rutherford grade II–III TAO, 75 patients with arteriosclerosis obliterans (ASO) and 65 healthy volunteers. " 03/01/1988 - "The survival rate of patients with TAO was higher than that of patients with arteriosclerosis obliterans. " 01/01/2004 - "Comparing the histology and immunohistochemistry of TAO especially with those of arteriosclerosis obliterans (ASO) and thromboembolism in two larger studies, we recently identified several features with significant meaning for the differential diagnosis. " 01/01/2000 - "To investigate the morphological features that differentiate TAO from arteriosclerosis obliterans (ASO) or thromboembolism, and to clarify the morphological independence of TAO, we studied 94 amputated specimens of lower extremities, including 31 specimens from patients with a clinical diagnosis of TAO and 31 autopsy specimens as control cases. " 01/01/1984 - "Although rFU was within normal limits in patients with arteriosclerosis obliterans (ASO) and thromboangitis obliterans (TAO), delta rFU of the whole leg was significantly decreased from the normal value of 3.41 +/- 0.45 to 1.95 +/- 0.40 for ASO (P less than 0.001) and 1.82 +/- 0.47 for TAO (P less than 0.001). "
9.	Pentoxifylline (Trental)FDA LinkGeneric 01/01/1985 - "A study was carried out in 17 patients with arteriosclerosis obliterans to assess the effectiveness of treatment with pentoxifylline ('Trental') and to investigate its possible mechanism of action. " 06/13/1988 - "[Effect of long-term pentoxifylline treatment on selected parameters of the fibrinolytic system in patients with arteriosclerosis obliterans of the legs]." 01/01/1985 - "Beneficial results of pentoxifylline ('Trental') therapy in arteriosclerosis obliterans: possible mechanism of action." 01/01/1987 - "Some haemorheological factors in patients with arteriosclerosis obliterans after treatment of trental." 01/01/1985 - "In experiments ex vivo, no release of a disaggregatory substance into blood was observed after a single bolus intravenous injection of pentoxifylline in patients with arteriosclerosis obliterans. "
10.	Endothelin-1 (Endothelin 1)IBA 07/01/2021 - "This study aims to investigate the role of endothelin-1 (ET-1) and C-reactive protein (CRP) in restenosis after intervention of lower extremity arteriosclerosis obliterans. " 07/01/2021 - "Clinical Significance of Endothelin-1 And C Reaction Protein in Restenosis After the Intervention of Lower Extremity Arteriosclerosis Obliterans." 04/01/2010 - "Beraprost sodium tended to decrease endothelin-1 levels and improved symptoms of intermittent claudication in patients with arteriosclerosis obliterans." 11/01/2003 - "Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans." 07/01/2021 - "Endothelin-1 and C Reactive Protein as Potential Biomarkers for Restenosis in Patients with Arteriosclerosis Obliterans."

Therapies and Procedures

1.	Therapeutics 10/01/2014 - "Endovascular therapy for complex arteriosclerosis obliterans of the lower extremities is effective and safe." 01/01/1996 - "[31P magnetic resonance spectroscopy: a noninvasive method for studying skeletal muscle metabolism in patients with arteriosclerosis obliterans of the vessels of the lower extremities and for assessing the efficacy of vasoprostan therapy]." 01/01/2022 - "This study was designed to analyse the clinical efficacy of interventional therapy on lower extremity arteriosclerosis obliterans (LEASO) and prognostic factors. " 01/01/2023 - "Retracted: Clinical Efficacy of Interventional Therapy on Lower Extremity Arteriosclerosis Obliterans and Prognostic Factors." 01/01/2022 - "Clinical Efficacy of Interventional Therapy on Lower Extremity Arteriosclerosis Obliterans and Prognostic Factors."
2.	Blood Component Removal (Apheresis) 07/01/1992 - "Hyperlipidemia was rapidly corrected after the initial two aphereses, whereas clinical signs of arteriosclerosis obliterans (ASO), such as coldness of the legs in 17 of 19 patients (89.5%), intermittent claudication in 14 of 17 patients (82.4%), foot pain at rest in 15 of 18 patients (83.3%), poor arterial pulsation in 12 of 16 patients (75.0%), and diminution of ulcer/necrosis in 3 of 5 patients (60.0%), improved in parallel. " 01/01/2007 - "Efficacy of low-density lipoprotein apheresis in arteriosclerosis obliterans of the lower extremities: two cases with marked alleviation of clinical symptoms." 01/01/1993 - "We reported here a case of arteriosclerosis obliterans (ASO) in which clinical symptoms and signs were improved after repeated LDL apheresis. " 01/01/1993 - "[Arteriosclerosis obliterans that was improved by LDL apheresis]." 11/01/2012 - "Increment of cerebral blood flow by LDL-apheresis in dialysis patients with arteriosclerosis obliterans: a pilot study."
3.	Limb Salvage 12/01/2021 - " deep vein arterialization might be helpful for limb salvage in patients with non-option CLTI.A brief review about the treatment of lower extremity arteriosclerosis obliterans is performed based on latest literatures and institutional experience.Understanding" 12/01/2021 - " deep vein arterialization might be helpful for limb salvage in patients with non-option CLTI.A brief review about the treatment of lower extremity arteriosclerosis obliterans is performed based on latest literatures and institutional experience.Understanding" 01/01/2018 - "Between January 2000 and December 2013, there were 333 consecutive arteriosclerosis obliterans patients with CLI who underwent 401 PIMB procedures for limb salvage (LS). " 02/18/2016 - "Stent implantation can increase the cost and short term effective rate at the same time and is not superior to PTA on the long term effective rate and limb salvage rate for femoral and popliteal artery lesion resulted from arteriosclerosis obliterans." 04/01/1986 - "An aggressive approach to limb salvage for infrainguinal arteriosclerosis obliterans in the elderly is recommended because of the generally poor rehabilitation and poor quality of life resulting from primary amputation. "
4.	Transplantation 07/01/2015 - "To assess the long-term effectiveness and safety of autologous bone marrow mononuclear cells (BM-MNC) transplantation in the treatment of critical diabetic lower arteriosclerosis obliterans (ASO). " 07/01/2015 - "[A FOLLOW-UP STUDY ON AUTOLOGOUS BONE MARROW MONONUCLEAR CELLS TRANSPLANTATION FOR CRITICAL LOWER ARTERIOSCLEROSIS OBLITERANS IN DIABETIC PATIENTS]." 08/01/2007 - "Quality of life improvement and long-term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis." 08/01/2007 - "Intramuscular transplantation of autologous bone marrow-mononuclear cells (BM-MNC) has been recently reported as improving the symptoms and clinical manifestations in patients with severely ischemic limbs, mostly caused by arteriosclerosis obliterans. " 06/01/2003 - "To evaluate the clinical efficacy of mobilized autologous peripheral blood stem cells (PBSC) transplantation in a 48 years old patient with lower limb arteriosclerosis obliterans (ASO). "
5.	Autologous Transplantation 03/01/2004 - "Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities." 05/01/2009 - "[New possibilities of the extremity revascularization in chronic ischemia: induction of angiogenesis by the bone marrow aspirate autotransplantation in patients with arteriosclerosis obliterans in the vessels of the lower extremities]." 04/01/2004 - "[Therapeutic angiogenesis by autologous transplantation of bone-marrow cells in a patient with progressive limb ischemia due to arteriosclerosis obliterans: a case report]." 12/01/2007 - "Previous studies have suggested that the lower limb arteriosclerosis obliterans (LASO) could be improved by autologous transplantation of either bone marrow mononuclear cells (BM-MNC) or G-CSF-mobilized peripheral blood mononuclear cells (M-PBMNC). "